Orchid Pharmaceuticals today said it has received tentative approval from the US regulator for Sumatriptan Succinate Tablets, used in the treatment of acute migraine headache.
The Chennai-based company has received a tentative go-ahead from the US Food and Drug Administration (US FDA) for its drug Sumatriptan Succinate Tablets, the company said in a filling to the Bombay Stock Exchange.
The tablets would be available in the strengths of 25 mg, 50 mg and 100 mg, the filing said.
The drug is used specifically for treating nerves and blood vessels that are believed to trigger total migraine.
Shares of Orchid Pharma were trading at Rs 105.20, down 3.62% on the BSE.
